CABA · Cabaletta Bio
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $1.74
Note written ·
Price against the kill line
26.4% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $1.74, on record since 11 November 2026. The shares are down 55.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $1.74, which would show the shares leading the S&P 500 and prove this call wrong; so would positive RESET-Myositis topline results reported ahead of the guided second half of 2027.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Free cash flow, four quarters ($M)
- −163
- Free-cash-flow yield (%)
- −58.9
All filed numbers
What Cabaletta Bio reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −190 | −53.1 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +82.7 |
| Operating cash flow ($M) | −162 |
| Capital spending ($M) | 0.3 |
| Free cash flow ($M) | −163 |
| Cash and short-term investments ($M) | 299 |
| Debt ($M) | Not available |
| Net cash, cash less debt ($M) | Not available |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 284 |
| Market value ($M) | 276 |
| Enterprise value, market value plus net debt ($M) | Not available |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not available |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.0 |
| Free-cash-flow yield (%) | −58.9 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 18.2% of shares outstanding sold short, 7.2 days of average trading to cover, +1.7% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $296K | $0 |
The thesis
Cabaletta Bio's shares are more likely to lag than beat the S&P 500 over the next three months, because the registrational myositis result that would re-rate them is not due until the second half of 2027. The shares closed at $1.33 on 12 November 2026, 68.6% below the 52-week intraday high of $4.23 set on 6 May 2026.
Rese-cel is Cabaletta's CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for autoimmune disease. In its third-quarter 2026 report on 5 November 2026, the company said cash, cash equivalents and short-term investments were $299.4 million at 30 September 2026 and fund operations into the first quarter of 2028 (company release, as summarised by BiopharmaWatch). The same report moved RESET-Myositis topline results to the second half of 2027 and planned a myositis biologics license application for the first quarter of 2028.
The market has already absorbed the American College of Rheumatology (ACR) data of 8 November 2026 and 9 November 2026. The shares closed at $1.30 on 6 November 2026, rose to $1.50 on 9 November 2026 and fell back to $1.33 on 12 November 2026. The three-month price change is −51.6%.
Bullish and bearish views on Cabaletta Bio, Inc.
The bull case on Cabaletta Bio, Inc. (CABA), in brief: funding now outlasts the data date. The bear case: the pivotal data moved later.
Bull case
- Funding now outlasts the data date. Cash was $299.4 million at 30 September 2026, against $225.1 million at 30 June 2026, and runway extends into the first quarter of 2028 (Q3 2026 release, 5 November 2026). About $115.0 million came from warrant exercises ahead of the 12 September 2026 expiry, per the BiopharmaWatch summary.
- One-year data held up at ACR. In dermatomyositis, 6 of 6 patients kept an immunomodulator-free response through one year. In lupus nephritis, 5 of 5 patients with repeat biopsies reached immunomodulator-free remission (company presentations, 8 November 2026). The cohorts are 5 to 7 patients each, too small to support a firm conclusion.
- Systemic sclerosis cohort is open. The Q3 release says the roughly 25-patient registrational RESET-SSc cohort has been initiated and is enrolling.
- Safety profile is mild so far. Across 71 treated patients, cytokine release syndrome was absent or Grade 1 in 67 and Grade 2 in 4 (ACR safety poster, 9 November 2026).
- Analyst targets sit far above the shares. Citigroup kept Buy and lowered its target to $8 on 9 November 2026. Wells Fargo has Equal-Weight with a $3 target since 14 August 2026 (Benzinga).
Bear case
- The pivotal data moved later. Topline results shifted from mid-2027 to the second half of 2027, and the filing target is the first quarter of 2028 (Q3 2026 release, 5 November 2026). The company has guided no efficacy readout for roughly a year.
- Costs are rising. Research and development expense was $47.1 million in the third quarter against $39.8 million a year earlier, and the net loss was $53.1 million, or $0.28 per share (BiopharmaWatch summary of the release). The per-share loss was smaller than the $0.33 consensus estimate (Benzinga, 5 November 2026).
- Dilution already happened and can recur. Warrant exercises added shares, and an at-the-market stock-sale program remains active. Cabaletta priced a $150 million underwritten offering on 4 May 2026.
- Good data did not lift the shares. The close was $2.55 on 18 September 2026, $1.89 on 1 October 2026 and $1.62 on 14 October 2026. After the ACR presentations the shares closed at $1.50 on 9 November 2026 and $1.33 on 12 November 2026.
- Analysts are cutting targets. Citigroup lowered its target to $8 on 9 November 2026 and Wells Fargo cut to $3 on 14 August 2026 (Benzinga).
Price setup
The last close was $1.33 on 12 November 2026. The 52-week closing low is $1.28, set on 5 November 2026, five cents below the latest close. The 50-day average is $1.97 and the 200-day average is $2.8 (adjusted daily closes as of 12 November 2026), so the shares sit below both.
Overhead closes are $1.50 on 9 November 2026, $1.62 on 14 October 2026, $1.89 on 1 October 2026 and $2.55 on 18 September 2026. The shares fell 8.3% on 12 November 2026 from $1.45 on 11 November 2026 with no company news in the 30 days since the ACR presentations.
No earnings date falls inside the next 30 days. T. Rowe Price Investment Management filed an amended Schedule 13G on 7 November 2026; the news headline does not state the direction of the stake change.
Catalysts ahead
- 2H 2027 (guided): RESET-Myositis registrational topline results. The clinical result that decides the case; the date moved from mid-2027 in the 5 November 2026 report.
- 1Q 2028 (guided): Planned myositis biologics license application. Marks the step from trial data to a regulatory filing and sits within the runway guided into the first quarter of 2028.
What would change the view
A daily close above $1.74, which would show the shares leading the S&P 500 and prove this call wrong; so would positive RESET-Myositis topline results reported ahead of the guided second half of 2027.
What it trades with
Cabaletta trades with clinical-stage small-cap biotech and with other developers of CAR-T therapy for autoimmune disease. Sector financing conditions and peer CAR-T data move the shares alongside company news. No measured correlation figures are available.
The evidence, claim by claim (7)
- Cash, cash equivalents and short-term investments were $299.4 million at 30 September 2026, including about $115.0 million from warrant exercises; runway into the first quarter of 2028. Cabaletta Bio Q3 2026 results release, via BiopharmaWatch summary · as of
- Q3 2026 net loss was $53.1 million ($0.28 per share); research and development expense was $47.1 million against $39.8 million a year earlier. Cabaletta Bio Q3 2026 results release, via BiopharmaWatch summary · as of
- RESET-Myositis topline results guided to the second half of 2027; myositis biologics license application planned for the first quarter of 2028. Cabaletta Bio Q3 2026 results release, via BiopharmaWatch summary · as of
- Dermatomyositis: 6 of 6 patients kept an immunomodulator-free response through one year; lupus nephritis: 5 of 5 patients with repeat biopsies reached immunomodulator-free remission. Cabaletta ACR Convergence 2026 presentations, via BiopharmaWatch · as of
- Across 71 treated patients, cytokine release syndrome was none or Grade 1 in 67 and Grade 2 in 4. Cabaletta ACR Convergence 2026 safety poster, via BiopharmaWatch · as of
- Citigroup maintained Buy on Cabaletta Bio and lowered its price target to $8. Benzinga · as of
- The shares closed at $1.33, below the 50-day average of $1.97 and the 200-day average of $2.8; the three-month price change was −51.6%. Adjusted daily closes · as of
Sources
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
ABCL
AbCellera Biologics
AbCellera's shares look more likely to lag the S&P 500 over three months, because the case rests on unproven repeat dosing of ABCL635, its…
IBRX
ImmunityBio
ImmunityBio's third-quarter Anktiva revenue of $48.7 million fell below the second quarter's $50.7 million, and the shares are more likely…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…